|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Locke M, Heywood M, Fawell S and Mackenzie
IC: Retention of intrinsic stem cell hierarchies in
carcinoma-derived cell lines. Cancer Res. 65:8944–8950. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh SK, Clarke ID, Terasaki M, et al:
Identification of a cancer stem cell in human brain tumors. Cancer
Res. 63:5821–5828. 2003.PubMed/NCBI
|
|
6
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
et al: Isolation and in vitro propagation of tumorigenic breast
cancer cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eramo A, Lotti F, Sette G, et al:
Identification and expansion of the tumorigenic lung cancer stem
cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tirino V, Camerlingo R, Franco R, et al:
The role of CD133 in the identification and characterisation of
tumour-initiating cells in non-small-cell lung cancer. Eur J
Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bonnomet A, Brysse A, Tachsidis A, et al:
Epithelial-to-mesenchymal transitions and circulating tumor cells.
J Mammary Gland Biol Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005.
|
|
12
|
Pantel K and Brakenhoff RH: Dissecting the
metastatic cascade. Nat Rev Cancer. 4:448–456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klein CA: Parallel progression of primary
tumours and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pantel K, Alix-Panabières C and Riethdorf
S: Cancer micrometastases. Nat Rev Clin Oncol. 6:339–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franco R, Pirozzi G, Scala S, Cantile M,
Scognamiglio G, Camerlingo R, Botti G and Rocco G: CXCL12-binding
receptors expression in non-small cell lung cancer relates to
tumoral microvascular density and CXCR4 positive circulating
tumoral cells in lung draining venous blood. Eur J Cardiothorac
Surg. 41:368–375. 2012. View Article : Google Scholar
|
|
17
|
Dick JE: Future prospects for animal
models created by transplanting human haematopoietic cells into
immune-deficient mice. Res Immunol. 145:380–384. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma S, Chan KW, Hu L, et al: Identification
and characterization of tumorigenic liver cancer stem/progenitor
cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen YC, Hsu HS, Chen YW, et al: Oct-4
expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS One. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, et al: Highly tumorigenic lung cancer
CD133+ cells display stem-like features and are spared
by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286.
2009.PubMed/NCBI
|
|
22
|
Levina V, Marrangoni AM, DeMarco R,
Gorelik E and Lokshin AE: Drug-selected human lung cancer stem
cells: cytokine network, tumorigenic and metastatic properties.
PLoS One. 3:e30772008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Basak SK, Veena MS, Oh S, Huang G,
Srivatsan E, et al: The malignant pleural effusion as a model to
investigate intratumoral heterogeneity in lung cancer. PLoS One.
4:e58842009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Y and Wu PY: CD133 as a marker for
cancer stem cells: progresses and concerns. Stem Cells Dev.
18:1127–1134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leung EL, Fiscus RR, Tung JW, et al:
Non-small cell lung cancer cells expressing CD44 are enriched for
stem cell-like properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li CY, Li BX, Liang Y, et al: Higher
percentage of CD133+ cells is associated with poor
prognosis in colon carcinoma patients with stage IIIB. J Transl
Med. 7:562009.PubMed/NCBI
|
|
27
|
Xi HQ and Zhao P: Clinicopathological
significance and prognostic value of EphA3 and CD133 expression in
colorectal carcinoma. J Clin Pathol. 64:498–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Artells R, Moreno I, Diaz T, et al: Tumour
CD133 mRNA expression and clinical outcome in surgically resected
colorectal cancer patients. Eur J Cancer. 46:642–649. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Horst D, Kriegl L, Engel J, et al: CD133
expression is an independent prognostic marker for low survival in
colorectal cancer. Br J Cancer. 99:1285–1289. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Metellus P, Nanni-Metellus I, Delfino C,
et al: Prognostic impact of CD133 mRNA expression in 48
glioblastoma patients treated with concomitant radiochemotherapy: a
prospective patient cohort at a single institution. Ann Surg Oncol.
18:2937–2945. 2011. View Article : Google Scholar
|
|
31
|
Sasaki A, Kamiyama T, Yokoo H, et al:
Cytoplasmic expression of CD133 is an important risk factor for
overall survival in hepatocellular carcinoma. Oncol Rep.
24:537–546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ishigami S, Ueno S, Arigami T, et al:
Prognostic impact of CD133 expression in gastric carcinoma.
Anticancer Res. 30:2453–2457. 2010.PubMed/NCBI
|
|
33
|
Nakamura M, Kyo S, Zhang B, et al:
Prognostic impact of CD133 expression as a tumor-initiating cell
marker in endometrial cancer. Hum Pathol. 41:1516–1529. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Silva IA, Bai S, McLean K, et al: Aldehyde
dehydrogenase in combination with CD133 defines angiogenic ovarian
cancer stem cells that portend poor patient survival. Cancer Res.
71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Woo T, Okudela K, Mitsui H, et al:
Prognostic value of CD133 expression in stage I lung
adenocarcinomas. Int J Clin Exp Pathol. 4:32–42. 2010.PubMed/NCBI
|
|
36
|
Levina V, Marrangoni A, Wang T, et al:
Elimination of human lung cancer stem cells through targeting of
the stem cell factor-c-kit autocrine signaling loop. Cancer Res.
70:338–346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maheswaran S and Haber DA: Circulating
tumor cells: a window into cancer biology and metastasis. Curr Opin
Genet Dev. 20:96–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gudemann CJ, Weitz J, Kienle P, et al:
Detection of hematogenous micrometastasis in patients with
transitional cell carcinoma. J Urol. 164:532–536. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Naito T, Tanaka F, Ono A, et al:
Prognostic impact of circulating tumor cells in patients with small
cell lung cancer. J Thorac Oncol. 7:512–519. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guzzo TJ, McNeil BK, Bivalacqua TJ,
Elliott DJ, Sokoll LJ and Schoenberg MP: The presence of
circulating tumor cells does not predict extravesical disease in
bladder cancer patients prior to radical cystectomy. Urol Oncol.
30:44–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
